SCHEMBL275959

SCHEMBL275959

c1ccc(-c2ccc(-c3c4ccccc4c(-c4ccc5ccccc5c4)c4ccc(-c5ccccn5)cc34)cc2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
KDM4E B2RXH2 2/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
PKM P14618 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
KLF5 Q13887 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
DCTPP1 Q9H773 1/20 0.43
DHODH Q02127 1/20 0.43
CYP1A1 P04798 2/20 0.41
CYP1B1 Q16678 2/20 0.41
SIRT2 Q8IXJ6 2/20 0.40
CYP1A2 P05177 4/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13658725 0.97 SMN1; SMN2 (0.50) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL10030057 0.96 SMN1; SMN2 (0.49) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL24812258 0.94 SMN1; SMN2 (0.46) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL15977771 0.94 SMN1; SMN2 (0.48) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL15977931 0.94 SMN1; SMN2 (0.48) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL17227659 0.94 KDM4E (0.52) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL12571761 0.93 KDM4E (0.51) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL10030067 0.92 SIRT2 (0.47) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL24813347 0.91 SMN1; SMN2 (0.45) SMN1; SMN2KDM4ELMNAMAPTPKM
SCHEMBL24811997 0.91 KDM4E (0.48) SMN1; SMN2KDM4ELMNAMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134035-B2 Preparation of asymmetric anthracene derivatives and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2012-03-13 US disclosed
US-8134035-B2 Preparation of asymmetric anthracene derivatives and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2012-03-13 US disclosed
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2011-03-17 US disclosed
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME AKR7A2, ACMSD, ALKBH3 SMN1; SMN2 4542/4885KDM4E 2577/4885LMNA 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.